Skip to content

Medication Repurposing to Stop Cognitive Decline in Dementia

Translational Identification of Medication Repurposing Candidates to Slow Cognitive Decline in Dementia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05817188
Enrollment
100000
Registered
2023-04-18
Start date
2023-01-01
Completion date
2025-03-01
Last updated
2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Dementia, Dementia Disorders

Keywords

medication, repurposing, cognitive decline, dementia, Mini-Mental State Examination

Brief summary

Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. Many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia. Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has \>100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination-MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. The investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. The investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.

Interventions

OTHERNo intervention

No intervention was applied

Sponsors

Region Stockholm
CollaboratorOTHER_GOV
KTH Royal Institute of Technology
CollaboratorOTHER
Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All patients with dementia registered in SveDem.

Exclusion criteria

Lack of Swedish personal identification number or coordination number.

Design outcomes

Primary

MeasureTime frameDescription
Cognitive declineThrough study completion, at least 1 yearThe data on cognitive decline will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.

Secondary

MeasureTime frameDescription
Rate of nursing home placementThrough study completion, at least 1 yearData will be obtained from the social services registry.
MortalityThrough study completion, at least 1 yearData about date and cause(s) of death will be collected from The Cause of Death Register.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026